Targeted Alpha Therapy in mCRPC (Metastatic Castration-Resistant Prostate Cancer) Patients: Predictive Dosimetry and Toxicity Modeling of 225Ac-PSMA (Prostate-Specific Membrane Antigen)-Reference-Cited by-同舟云学术

Targeted Alpha Therapy in mCRPC (Metastatic Castration-Resistant Prostate Cancer) Patients: Predictive Dosimetry and Toxicity Modeling of 225Ac-PSMA (Prostate-Specific Membrane Antigen)

Published:2020-11-05 Issue: Volume:10 Page:
ISSN:2234-943X
Container-title:Frontiers in Oncology
language:
Short-container-title:Front. Oncol.

Author:

Belli Maria Luisa,Sarnelli Anna,Mezzenga Emilio,Cesarini Francesco,Caroli Paola,Di Iorio Valentina,Strigari Lidia,Cremonesi Marta,Romeo Antonino,Nicolini Silvia,Matteucci Federica,Severi Stefano,Paganelli Giovanni

Publisher

Frontiers Media SA

Subject

Cancer Research,Oncology

Reference60 articles.

1. Receptor radionuclide therapy of tumors: a road from basic research to clinical applications3757 BodeiL PaganelliG MarianiG 16513604J Nucl Med.472006

2. Peptide receptor radiotherapy: current approaches and future directions;Kong;Curr Treat Options Oncol.,2019

3. 177Lu-PSMA radioligand therapy for prostate cancer;Fendler;J Nucl Med,2017

4. 177Lu-labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy;Baum;J Nucl Med.,2016

5. [177 Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study;Hofman;Lancet Oncol.,2018

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tubarial salivary glands show a low relative contribution to functional salivary gland tissue mass;Annals of Nuclear Medicine;2024-07-26

2. Prostate-specific Membrane Antigen: Alpha-labeled Radiopharmaceuticals;PET Clinics;2024-07

3. Quantitative SPECT/CT imaging of actinium-225 for targeted alpha therapy of glioblastomas;EJNMMI Physics;2024-05-09

4. Salivary excretion of systemically injected [18F]DCFPyL in prostate cancer patients undergoing PSMA scans;Frontiers in Oncology;2024-04-23

5. Activity quantification and dosimetry in radiopharmaceutical therapy with reference to 177Lutetium;Frontiers in Nuclear Medicine;2024-03-28